1 2 aim
Givinostat for Becker muscular dystrophy- A randomized, placebo-controlled, double-blind study

Monthly #apaperaday wrap-up: March 2024

Prof. Annemieke Aartsma-Rus is taking on a challenge by reading and commenting on a paper a day. She shares her insights, findings and thoughts via her @oligogirl Twitter account. Each month, a curated selection of the relevant papers for Duchenne and Becker muscular dystrophy are presented by the World Duchenne Organization. See below the overview of March 2024.

Must Must read

  • Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS) > Read more

Must reads

  • Characteristics of Patients Receiving Novel Muscular Dystrophy Drugs in Trials vs Routine Care > Read more
  • Increase in Full-Length Dystrophin by Exon Skipping in Duchenne Muscular Dystrophy Patients with Single Exon Duplications > Read more
  • Spending on Targeted Therapies for Duchenne Muscular Dystrophy > Read more
  • HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients > Read more
  • EURO-NMD registry: federated FAIR infrastructure, innovative technologies and concepts of a patient-centred registry for rare neuromuscular disorders > Read more
  • Design requirements of upper extremity supports for daily use in Duchenne muscular dystrophy with severe muscle weakness > Read more

Interesting papers

  • The IAAM LTBP4 Haplotype is Protective Against Dystrophin-Deficient Cardiomyopathy > Read more
  • Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls > Read more
  • Longitudinal data of serum creatine kinase levels and motor, pulmonary, and cardiac functions in 337 patients with Duchenne muscular dystrophy > Read more

Additional reading

  • Selection-free precise gene repair using high-capacity adenovector delivery of advanced prime editing systems rescues dystrophin synthesis in DMD muscle cells > Read more
  • Evolution of neuropsychological and behavioral profile in a cohort of pediatric patients with Becker muscular dystrophy in a longitudinal study > Read more
  • The role of ataluren in the treatment of ambulatory and non-ambulatory children with nonsense mutation duchenne muscular dystrophy > Read more
  • Decreased quality of life in Duchenne muscular disease patients related to functional neurological and cardiac impairment > Read more


We are grateful for prof. Aartsma-Rus for allowing us to share her daily recaps. Follow @oligogirl on Twitter to stay on top of the latest #apaperaday tweets, or subscribe to the WDO Newsletter to receive the monthly must-reads in your inbox.


About professor Annemieke Aartsma-Rus

Prof. Dr. Annemieke Aartsma-Rus is a professor of Translational Genetics at the Department of Human Genetics of the Leiden University Medical Center. Since 2013 she has a visiting professorship at the Institute of Genetic Medicine of Newcastle University (UK).

Her work currently focuses on developing antisense-mediated exon skipping as a therapy for Duchenne muscular dystrophy. In addition, in collaborative efforts she aims to bridge the gap between different stakeholders (patients, academics, regulators and industry) involved in drug development for rare diseases.

In 2013 she was elected a member of the junior section of the Dutch Royal Academy of Sciences (KNAW), which consists of what are considered the top 50 scientists in the Netherlands under 45. From 2015 to 2022, she was selected as the most influential scientist in Duchenne muscular dystrophy by Expertscape.